Navigation Links
Actavis Launches Generic Version of Flomax(R) In The U.S.
Date:4/27/2010

MORRISTOWN, N.J., April 27 /PRNewswire/ -- Actavis Inc., today began shipping Tamsulosin capsules to its customers in the United States. The generic equivalent to Flomax®, Tamsulosin is used to treat benign prostatic hyperplasia (BPH). Actavis is partnering with Synthon Pharmaceuticals to launch and market Tamsulosin capsules in the United States.  

Actavis offers Tamsulosin in a 0.4 mg strength capsule. Annual sales of Flomax® capsules in the U.S. were approximately US$2.17 billion for the 12 months ending December 2009, according to IMS Health data.  

About Actavis Inc.

Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one quarter of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing facilities in Elizabeth, NJ; Little Falls, NJ; Totowa, NJ; and Lincolnton, NC. Actavis also has research and development facilities in Owings Mills, MD and Sunrise, FL; and a packaging facility in Totowa, NJ.

About Actavis Group

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals.  The company has operations in 40 countries, with more than 10,500 employees.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis Receives Approval of Alprazolam ODT in the U.S.
2. The Vanishing Oath, the First Physician-Focused Documentary on the Dangers of the American Healthcare System, Launches on DVD May 5
3. NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center and R&D Laboratory in Cambridge, Massachusetts
4. FDA Launches Initiative to Reduce Infusion Pump Risks
5. Usability Sciences Corporation Launches WebIQ Pharma - An Intelligent Survey Tool That Allows Pharma Sites to Measure and Improve Website Effectiveness
6. EndoChoice(R) Launches CEU Program on Proper Endoscope Reprocessing and a Line of Flexible Endoscope Reprocessing Products
7. VisEn Launches New VivoTag(R) 680 XL Fluorescence Molecular Imaging Label
8. CareFusion Launches New Pyxis ProcedureStation(TM) Radio Frequency Identification System at Association of Perioperative Registered Nurses 57th Annual Congress
9. ERT Launches Centralized Cardiac Safety 2.0: A Revolutionary New Approach to ECG Management in Clinical Trials
10. Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System
11. Blizzard, McCarthy & Nabers Launches ReglanJustice.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/27/2016)... , Schweiz, April 27, 2016 ... Sachs CEO Forums in Zürich gab Strekin ... führenden Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens ... wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie mit ... Frankreich angeworben. STR001 wird während der Operation ...
(Date:4/27/2016)... , April 27, 2016 ... titled, "Skincare Devices Market - Global Industry Analysis, Size, ... to the report, the global skincare devices market was ... anticipated to expand at a CAGR of 10.1% from ... 2023. Browse the full Skincare Devices Market (Treatment ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... , ... Dr. Philip Shindler, dentist in Agoura Hills , now offers ... many necessary dental treatments could require multiple appointments to complete. This could mean taking ... time. Not only could this be inconvenient, but it could also be overwhelmingly unpleasant ...
(Date:5/2/2016)... Rhinebeck, NY (PRWEB) , ... May 02, 2016 , ... ... Valley, reopened for its 2016 guest season which runs through October. Omega is offering ... talks . , “There has never been such widespread interest in or ...
(Date:5/2/2016)... ... May 02, 2016 , ... Visceral ... organs, such as the kidneys, liver and pancreas. If not properly addressed, visceral ... board-certified physician in Internal Medicine, Medical Oncology and Palliative Care, warns against the ...
(Date:5/2/2016)... ... May 02, 2016 , ... Pregnancy Awareness Month offers a great time to ... , “If you are ready to have a baby, it’s best to get started ... Babies is your Personal Conception & Pregnancy Organizer, written for women who plan on ...
(Date:5/2/2016)... ... 02, 2016 , ... Consultative health care market research firm ... and Duane Reed, VP of business development of AJMC Strategic Solutions, will be ... (PBIRG) General Meeting from May 15-17 at the Boca Raton Resort & ...
Breaking Medicine News(10 mins):